Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arkh Patol ; 66(5): 45-9, 2004.
Artigo em Russo | MEDLINE | ID: mdl-15575388

RESUMO

Extraovarian malignant Brenner tumour in a female of 35. Rapid infiltrating growth with the destruction of tumour. All extraovarian tumours described so far were benign, located in the mesosalpinx, uterus or vagina. In this case the starting point of the tumour was in the vagina wall or in the recto-vaginal septum. Histological picture produced difficulties in establishing histogenesis of malignancy. The true nature of the tumour was established only immunohistochemically.


Assuntos
Tumor de Brenner/patologia , Neoplasias Pélvicas/patologia , Adulto , Feminino , Humanos , Ovário
2.
J Clin Oncol ; 11(5): 937-42, 1993 May.
Artigo em Inglês | MEDLINE | ID: mdl-8387578

RESUMO

PURPOSE: A study was undertaken to improve our understanding of the clinicopathologic features and therapeutic outcome for adults with primary Ki-1 anaplastic large-cell lymphoma (ALCL). PATIENTS AND METHODS: A retrospective review of records of 31 adult patients with primary Ki-1 ALCL was performed. The analysis included stage and distribution of disease, tumor-cell phenotype, response to initial and salvage therapy, and disease-free and overall survival. RESULTS: The median age of patients was 44 years (range, 16 to 86). Forty-eight percent of patients tested had lymphomas of T-cell phenotype, 30% lymphomas of B-cell phenotype, and 22% of non-T-, non-B-cell phenotype. Twenty-nine percent of patients had stages I and II disease, 65% demonstrated extranodal involvement, and 32% had skin involvement at presentation. Most patients received intensive chemotherapy and 48% achieved a sustained complete remission (CR), with an additional 17% of patients treated successfully with salvage therapy. Stage was highly predictive of achieving a sustained CR, but bulk disease and B symptoms did not predict for relapse after initial therapy or survival. Of seven patients who underwent autologous bone marrow transplantation (ABMT), three remain disease-free 9 to 42 months after transplant. CONCLUSION: Patients with Ki-1 ALCL have a high frequency of advanced-stage disease and extranodal involvement and are more likely to have tumors of T-cell phenotype than patients with large-cell lymphoma. However, response to standard lymphoma chemotherapy is similar to other patients with large-cell lymphoma, with a high remission rate in early-stage disease. Patients with advanced-stage disease have a poor remission duration and may require more intensive therapy, as may also be the case with large-cell lymphoma.


Assuntos
Antígenos CD/análise , Antígenos de Neoplasias/análise , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Feminino , Seguimentos , Humanos , Antígeno Ki-1 , Linfoma Difuso de Grandes Células B/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Avaliação de Resultados em Cuidados de Saúde , Fenótipo , Estudos Retrospectivos , Terapia de Salvação
3.
Hum Pathol ; 22(1): 94-6, 1991 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1985085

RESUMO

A mediastinal ependymoma in a 35-year-old Caucasian woman is reported. The tumor was located in a paravertebral posterior mediastinal location. No continuity with the spinal canal or with the lung was identified. The diagnosis was confirmed by immunoperoxidase staining for glial fibrillary protein and by the presence of cilia within intracytoplasmic vacuoles. To the best of our knowledge, this is the second reported case of ependymoma in this location.


Assuntos
Ependimoma/patologia , Neoplasias do Mediastino/patologia , Adulto , Ependimoma/diagnóstico , Feminino , Humanos , Neoplasias do Mediastino/diagnóstico
4.
Curr Med Res Opin ; 8 Suppl 3: 25-37, 1983.
Artigo em Inglês | MEDLINE | ID: mdl-6617239

RESUMO

Indapamide, a newly developed antihypertensive agent with modest diuretic properties, reduced mean arterial pressure toward normal in dogs made hypertensive with salt and DOCA, while low-dose furosemide (0.1 mg per day) and hydrochlorothiazide (1 and 50 mg per day) did not result in similar degrees of blood pressure control. Indapamide, low-dose furosemide and hydrochlorothiazide treatment all resulted in similar decreases in body weight suggesting that the antihypertensive effect of indapamide occurs through a mechanism independent of contraction of extracellular fluid volume. Intravenous indapamide at doses of 0.3, 1.0 and 3.0 mg/kg caused progressive increases in sodium, potassium and chloride excretion when urine losses were replaced by isotonic saline to prevent extracellular fluid volume contraction. Only at 3.0 mg/kg did plasma potassium decrease significantly (2.92 +/- 0.03 to 2.69 +/- 0.05 mmol/l; p less than 0.05). Neither glomerular filtration rate (GFR) nor renal blood flow (flowmeter) decreased in a dose-related manner; however, effective renal plasma flow assessed by para-aminohippurate clearance did decrease about 15% at the highest dose (p less than 0.05). Proximal re-collection micropuncture studies demonstrated decreased proximal reabsorption. Cortical diluting segment reabsorption was decreased, but CNa + CH2O/GFR increased from 7% to 11% (p less than 0.05). These results indicate that, at doses up to 3.0 mg/kg, indapamide causes a natriuresis which is modest and similar to that seen with thiazides. No decrease in GFR or renal blood flow was observed. This drug apparently exerts a natriuretic effect through an inhibition of solute reabsorption in both the proximal nephron and the cortical diluting segment.


Assuntos
Diuréticos/administração & dosagem , Eletrólitos/metabolismo , Hipertensão/fisiopatologia , Indapamida/administração & dosagem , Túbulos Renais Proximais/metabolismo , Rim/fisiopatologia , Animais , Pressão Sanguínea/efeitos dos fármacos , Cloretos/metabolismo , Cães , Relação Dose-Resposta a Droga , Feminino , Furosemida/administração & dosagem , Taxa de Filtração Glomerular/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Hidroclorotiazida/administração & dosagem , Potássio/metabolismo , Circulação Renal/efeitos dos fármacos , Sódio/metabolismo
9.
Arch Surg ; 102(3): 172-4, 1971 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-4993462
10.
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...